Related Experiment Video

Updated: Oct 22, 2025

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
09:41

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

Published on: June 17, 2014

12.3K

Pharmacologically Targeting the WNT/β-Catenin Signaling Cascade: Avoiding the Sword of Damocles

Keane K Y Lai1, Michael Kahn2

  • 1Beckman Research Institute, City of Hope, Duarte, CA, USA.

Handbook of Experimental Pharmacology
|August 31, 2021
PubMed

Insights

Targeting WNT/β-catenin signaling, crucial for development and repair, is challenging. Despite its role in diseases like cancer, no drugs targeting this pathway are FDA-approved due to safety and efficacy hurdles.

Area of Science:

  • Cellular biology
  • Developmental biology
  • Molecular signaling

Background:

  • WNT/β-catenin signaling regulates key cellular processes including self-renewal, differentiation, and apoptosis.
  • Dysregulation of this pathway is implicated in various diseases such as cancer, fibrosis, and neurodegeneration.
  • Despite its importance, pharmacological targeting of WNT/β-catenin signaling has faced significant challenges.

Purpose of the Study:

  • To explore the reasons behind the difficulties in safely targeting the WNT/β-catenin signaling pathway.
  • To discuss current efforts and strategies aimed at developing effective WNT/β-catenin pathway inhibitors.

Main Methods:

  • Review of preclinical and clinical studies on WNT/β-catenin pathway inhibitors.
  • Analysis of the biological roles and regulatory mechanisms of WNT/β-catenin signaling.
  • Discussion of challenges in achieving therapeutic selectivity and safety.

Main Results:

  • Multiple WNT/β-catenin pathway inhibitors have been investigated preclinically.
  • Several agents have advanced to clinical trials, but none have received FDA approval.
  • The complexity of WNT/β-catenin signaling contributes to difficulties in therapeutic development.

Conclusions:

  • Safely and effectively targeting the WNT/β-catenin pathway remains a significant challenge in drug development.
  • Further research is needed to overcome hurdles related to specificity and potential toxicity.
  • Understanding the intricate roles of WNT/β-catenin signaling is crucial for future therapeutic strategies.
Keywords:
AntagonistCancerClinical trialsFibrosisInhibitorWNTβ-catenin

More Related Videos

The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

112.6K
Modeling Paracrine Noncanonical Wnt Signaling In Vitro11:14

Modeling Paracrine Noncanonical Wnt Signaling In Vitro

Published on: December 10, 2021

1.7K

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.3K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.7K
Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
2.5K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
14.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.2K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.0K